Natera (NTRA) Stock Price

Natera Price

NASDAQ·CLOSED
267.76USD-1.90 (-0.71 %)
Market closed

Revenue has compounded at 47.9% per year over the past 13 years to 2.31 B USD. Natera's net margin stands at -9.0%, up from -75.4% several years earlier. Analysts set a median price target of 267.75 USD, implying 0.0% below the current price. Of 27 analysts, 24 rate the stock a buy — an overall Buy consensus. The stock trades about 94% above its 52-week low.

Natera stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Natera over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Natera stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Natera's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Natera Stock Price History
DateNatera Price
7/31/2026267.76 USD
7/30/2026269.66 USD
7/29/2026254.50 USD
7/27/2026260.52 USD
7/23/2026264.69 USD
7/22/2026264.22 USD
7/21/2026267.18 USD
7/20/2026262.63 USD
7/17/2026271.39 USD
7/16/2026269.83 USD
7/15/2026277.37 USD
7/14/2026272.66 USD
7/13/2026268.31 USD
7/10/2026269.95 USD
7/9/2026281.85 USD
7/8/2026277.06 USD
7/7/2026281.27 USD
7/6/2026285.33 USD
7/2/2026279.32 USD
7/1/2026276.27 USD
6/30/2026271.45 USD
6/29/2026265.73 USD
6/26/2026261.91 USD
6/25/2026260.74 USD
6/24/2026259.97 USD
6/23/2026234.76 USD
6/22/2026222.34 USD
6/18/2026229.91 USD
6/17/2026229.13 USD
6/16/2026218.63 USD
6/15/2026215.73 USD
6/12/2026217.26 USD
6/11/2026214.64 USD
6/10/2026217.49 USD
6/9/2026222.82 USD
6/8/2026213.47 USD
6/5/2026219.08 USD
6/4/2026225.97 USD
6/3/2026210.25 USD
6/2/2026214.48 USD
6/1/2026221.73 USD
5/29/2026222.79 USD
5/28/2026205.38 USD
5/27/2026198.43 USD
5/26/2026202.16 USD
5/22/2026203.76 USD
5/21/2026207.56 USD
5/20/2026203.19 USD
5/19/2026196.04 USD
5/18/2026192.54 USD
5/15/2026186.36 USD
5/14/2026196.91 USD
5/13/2026195.32 USD
5/12/2026204.21 USD
5/11/2026199.14 USD
5/8/2026194.24 USD
5/7/2026219.82 USD
5/6/2026215.09 USD
5/5/2026206.77 USD
5/4/2026211.56 USD
5/1/2026207.28 USD
4/30/2026206.16 USD
4/29/2026194.75 USD
4/28/2026200.17 USD
4/27/2026204.39 USD
4/24/2026203.75 USD
4/23/2026201.14 USD
4/22/2026207.78 USD
4/21/2026205.42 USD
4/20/2026207.74 USD
4/17/2026208.40 USD
4/16/2026196.11 USD
4/15/2026207.19 USD
4/14/2026214.64 USD
4/13/2026201.90 USD
4/10/2026193.03 USD
4/9/2026203.00 USD
4/8/2026210.83 USD
4/7/2026209.27 USD
4/6/2026204.87 USD
4/2/2026207.98 USD
4/1/2026203.21 USD
3/31/2026199.99 USD
3/30/2026186.84 USD
3/27/2026182.65 USD
3/26/2026196.15 USD
3/25/2026197.37 USD
3/24/2026194.52 USD
3/23/2026200.09 USD
3/20/2026195.28 USD
3/19/2026202.73 USD
3/18/2026197.79 USD
3/17/2026198.38 USD
3/16/2026197.68 USD
3/13/2026187.85 USD
3/12/2026190.31 USD
3/11/2026196.61 USD
3/10/2026198.95 USD
3/9/2026205.22 USD
3/6/2026198.13 USD
3/5/2026197.14 USD
3/4/2026203.03 USD
3/3/2026207.04 USD
3/2/2026200.17 USD
2/27/2026208.04 USD
2/26/2026216.10 USD
2/25/2026211.83 USD
2/24/2026209.53 USD
2/23/2026209.35 USD
2/20/2026212.12 USD
2/19/2026216.36 USD
2/18/2026215.53 USD
2/17/2026211.25 USD
2/13/2026206.23 USD
2/12/2026207.84 USD
2/11/2026212.46 USD
2/10/2026211.65 USD
2/9/2026210.58 USD
2/6/2026203.04 USD
2/5/2026197.08 USD
2/4/2026205.61 USD
2/3/2026227.68 USD
2/2/2026231.10 USD
1/30/2026231.14 USD
1/29/2026231.48 USD
1/28/2026235.93 USD
1/27/2026240.34 USD
1/26/2026241.39 USD
1/23/2026241.58 USD
1/22/2026242.91 USD
1/21/2026242.78 USD
1/20/2026234.85 USD
1/16/2026231.25 USD
1/15/2026240.34 USD
1/14/2026239.19 USD
1/13/2026237.89 USD
1/12/2026235.45 USD
1/9/2026234.31 USD
1/8/2026239.56 USD
1/7/2026254.40 USD
1/6/2026248.74 USD
1/5/2026237.42 USD
1/2/2026228.84 USD
12/31/2025229.09 USD
12/30/2025229.98 USD
12/29/2025231.30 USD
12/26/2025233.74 USD
12/24/2025235.54 USD
12/23/2025235.40 USD
12/22/2025235.57 USD
12/19/2025231.96 USD
12/18/2025224.74 USD
12/17/2025225.49 USD
12/16/2025227.40 USD
12/15/2025228.40 USD
12/12/2025231.95 USD
12/11/2025231.05 USD
12/10/2025233.13 USD
12/9/2025235.53 USD
12/8/2025239.14 USD
12/5/2025244.55 USD
12/4/2025242.06 USD
12/3/2025238.21 USD
12/2/2025236.64 USD
12/1/2025234.25 USD
11/28/2025238.81 USD
11/26/2025237.12 USD
11/25/2025236.49 USD
11/24/2025238.58 USD
11/21/2025230.63 USD
11/20/2025225.55 USD
11/19/2025218.35 USD
11/18/2025213.65 USD
11/17/2025206.04 USD
11/14/2025204.28 USD
11/13/2025200.67 USD
11/12/2025209.50 USD
11/11/2025206.72 USD
11/10/2025206.63 USD
11/7/2025199.57 USD
11/6/2025198.48 USD
11/5/2025199.92 USD
11/4/2025196.45 USD
11/3/2025198.23 USD
10/31/2025198.93 USD
10/30/2025193.22 USD
10/29/2025192.81 USD
10/28/2025189.57 USD
10/27/2025192.22 USD
10/24/2025192.51 USD
10/23/2025195.00 USD
10/22/2025188.02 USD
10/21/2025186.88 USD
10/20/2025188.60 USD
10/17/2025181.69 USD
10/16/2025180.54 USD
10/15/2025179.42 USD
10/14/2025172.81 USD
10/13/2025174.17 USD
10/10/2025169.27 USD
10/9/2025173.06 USD
10/8/2025172.09 USD
10/7/2025168.53 USD
10/6/2025170.38 USD
10/3/2025167.35 USD
10/2/2025160.21 USD
10/1/2025161.61 USD
9/30/2025160.97 USD
9/29/2025163.09 USD
9/26/2025162.97 USD
9/25/2025163.66 USD
9/24/2025163.91 USD
9/23/2025172.83 USD
9/22/2025179.19 USD
9/19/2025181.11 USD
9/18/2025179.86 USD
9/17/2025175.43 USD
9/16/2025175.01 USD
9/15/2025172.16 USD
9/12/2025168.51 USD
9/11/2025173.81 USD
9/10/2025169.79 USD
9/9/2025176.37 USD
9/8/2025167.39 USD
9/5/2025168.02 USD
9/4/2025166.56 USD
9/3/2025167.53 USD
9/2/2025169.34 USD
8/29/2025168.25 USD
8/28/2025167.88 USD
8/27/2025163.04 USD
8/26/2025165.71 USD
8/25/2025162.47 USD
8/22/2025165.60 USD
8/21/2025161.95 USD
8/20/2025160.64 USD
8/19/2025160.12 USD
8/18/2025161.15 USD
8/15/2025163.02 USD
8/14/2025158.44 USD
8/13/2025157.70 USD
8/12/2025159.81 USD
8/11/2025157.04 USD
8/8/2025151.95 USD
8/7/2025141.08 USD
8/6/2025138.13 USD
8/5/2025140.12 USD
Access this data via the Eulerpool API
Get Free API Key

Natera Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.08 B USD
-446.25 M USD
-434.80 M USD
Jan 1, 2024
1.70 B USD
-222.29 M USD
-190.43 M USD
Jan 1, 2025
2.31 B USD
-309.91 M USD
-208.16 M USD
Jan 1, 2026 (e)
2.80 B USD
-1.12 B USD
-225.07 M USD
Jan 1, 2027 (e)
3.33 B USD
-1.33 B USD
-41.48 M USD
Jan 1, 2028 (e)
4.01 B USD
-1.61 B USD
211.73 M USD
Jan 1, 2029 (e)
4.73 B USD
-1.90 B USD
337.72 M USD
Jan 1, 2030 (e)
5.59 B USD
-2.24 B USD
732.92 M USD

Natera Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 2:21 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.190.220.210.260.300.390.630.821.081.702.312.803.334.014.735.59
19.5014.21-3.2322.3817.5129.4759.8531.2031.9556.7535.9721.2918.9820.6117.7418.24
40.5337.3333.8135.4141.7247.8349.1244.2745.4760.3264.8364.8364.8364.8364.8364.83
0.080.080.070.090.130.190.310.360.491.021.501.812.162.603.063.62
-0.06-0.10-0.13-0.12-0.12-0.22-0.46-0.54-0.45-0.22-0.31-1.12-1.33-1.61-1.90-2.24
-31.05-44.24-63.81-45.53-38.41-56.78-73.92-65.98-41.22-13.09-13.40-40.08-40.08-40.08-40.10-40.09
-70.00-95.00-136.00-128.00-124.00-229.00-471.00-547.00-434.00-190.00-208.00-225.00-41.00211.00337.00732.00
1,300.0035.7143.16-5.88-3.1384.68105.6816.14-20.66-56.229.478.17-81.78-614.6359.72117.21
50.4452.7654.1362.8378.2980.9192.5698.41119.30124.72136.72136.72136.72136.72136.72136.72
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Natera generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Natera retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Natera's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Natera has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Natera's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Natera stock margins

The Natera margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Natera. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Natera.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
49.09 %
-73.99 %
-75.42 %
Jan 1, 2022
44.37 %
-65.96 %
-66.79 %
Jan 1, 2023
45.52 %
-41.22 %
-40.16 %
Jan 1, 2024
60.30 %
-13.10 %
-11.22 %
Jan 1, 2025
64.85 %
-13.44 %
-9.03 %
Jan 1, 2026 (e)
64.85 %
-40.10 %
-8.05 %
Jan 1, 2027 (e)
64.85 %
-40.10 %
-1.25 %
Jan 1, 2028 (e)
64.85 %
-40.10 %
5.27 %

Natera Stock Revenue, EBIT, Earnings per Share

The Natera earnings per share therefore indicates how much revenue Natera has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
6.76 USD
-5.00 USD
-5.10 USD
Jan 1, 2022
8.33 USD
-5.50 USD
-5.57 USD
Jan 1, 2023
9.07 USD
-3.74 USD
-3.64 USD
Jan 1, 2024
13.61 USD
-1.78 USD
-1.53 USD
Jan 1, 2025
16.87 USD
-2.27 USD
-1.52 USD
Jan 1, 2026 (e)
20.10 USD
-8.20 USD
-1.62 USD
Jan 1, 2027 (e)
23.92 USD
-9.76 USD
-0.30 USD
Jan 1, 2028 (e)
28.86 USD
-11.78 USD
1.52 USD

Natera business model & stock analysis

Natera Inc. is an American company headquartered in San Carlos, California. It was founded in 2004 by Matthew Rabinowitz and has been listed on the NASDAQ under the ticker symbol "NTRA" since 2015. The company is a leading provider of diagnostic tests and analyses and specializes in genetic analysis and diagnostic technologies. Natera specializes in tests for various medical areas, particularly in oncology diagnostics. The company's vision is to improve the quality of life for millions of people worldwide by offering innovative diagnostic tests to detect diseases early and ensure optimal treatment. Natera offers a wide range of products tailored to the needs of consumers, physicians, and scientists. The company operates in three business areas: 1) Women's Health: Natera offers tests for women and couples to determine the risk of hereditary diseases. For example, the company offers a test that allows analysis of fetal DNA from the mother's blood, allowing detection of genetic abnormalities in the fetus before birth. Additionally, Natera offers the Panorama test, which provides tests for genetic anomalies in unborn babies that can be used to determine the risk for chromosomal abnormalities and genetic mutations. 2) Oncology: In the field of oncology, Natera offers a wide range of diagnostic tests targeting developments and trends in cancer research. The tests aim to enable accurate diagnosis and prognosis, as well as provide individualized treatment for each patient. The company offers tests that assess the current tumor growth and metastatic potential, enable determination of tumor burden in cells, and provide tests for specific mutations required for determining optimal treatment. 3) Genomic Analysis: In the field of genomic analysis, Natera offers a broad range of tests available to researchers and scientists. This includes genetic variants and biological mechanisms that cause diseases. The company is also committed to developing its tests through artificial intelligence (AI) and machine learning. The goal is to provide more accurate and faster results, improve clinical decisions, and advance research and development of new diagnostics. Conclusion: Natera is a leading company in the field of diagnostic tests and analyses in the field of genomic analysis. The company has a long history of research and development of innovative product solutions for the medical community. One important focus of the company is to improve women's health and be able to detect risks for genetic diseases early; the other focus is on oncology diagnostic tools to determine optimal treatment for cancer patients. The company is constantly striving to further develop its tests and integrate new research findings and technologies to support the medical science community.

Natera SWOT Analysis

Strengths

Natera Inc has a strong portfolio of innovative genetic testing products.

The company has established a solid reputation in the biotechnology industry.

Natera Inc has a strong financial position and has been experiencing consistent revenue growth.

Weaknesses

The company relies heavily on a limited number of key clients for a significant portion of its revenue.

Natera Inc faces intense competition in the genetic testing market.

The company's research and development expenses are high, which puts pressure on profitability.

Opportunities

The increasing adoption of genetic testing in healthcare presents significant growth opportunities.

Natera Inc can expand its product offerings to cater to a broader range of genetic testing needs.

International expansion into untapped markets can drive further revenue growth.

Threats

Changing regulations in the healthcare industry can impact the demand for genetic testing services.

New entrants and technological advancements may increase competition for Natera Inc.

Economic downturns or fluctuations can affect consumer spending on genetic testing.

Natera Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Natera Employees
Details
Date
Natera Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Natera Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Natera historical P/E ratio, EBIT multiple, and P/S ratio

Natera annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Natera shares outstanding

The number of shares of Natera was 136.72 M in 2025. This indicates how many shares Natera is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
92.56 M Stocks
Jan 1, 2022
98.41 M Stocks
Jan 1, 2023
119.30 M Stocks
Jan 1, 2024
124.72 M Stocks
Jan 1, 2025
136.72 M Stocks
Jan 1, 2026 (e)
136.72 M Stocks
Jan 1, 2027 (e)
136.72 M Stocks
Jan 1, 2028 (e)
136.72 M Stocks

Current Natera forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.96 %
Buy
88.89 % (24)
Hold
11.11 % (3)
Sell
0.00 % (0)
12M Price Target
267.75
Last Price
267.76
Currency
USD
12M Return Potential
-0.00 %
LTM Return
0 %

Natera Analyst Rating Actions

DateFirmActionRatingReliability
7/14/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
7/9/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight60
7/6/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
6/29/2026
Guggenheim
Guggenheim
MaintainedBuy30
6/24/2026
BTIG
BTIG
MaintainedBuy–
6/24/2026
Barclays
Barclays
MaintainedOverweight33
6/23/2026
BTIG
BTIG
MaintainedBuy–
6/5/2026
Goldman Sachs
Goldman Sachs
DowngradeBuyNeutral–
5/11/2026
BTIG
BTIG
MaintainedBuy–
5/8/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Natera Earnings Calls

2025

Natera Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/5/2026-0.50USD-675.02 MUSD-2026 Q2
5/7/2026-0.55USD-630.04 MUSD-2026 Q1
3/4/2026-0.53USD-604.26 MUSD-2025 Q4
11/12/2024-0.59USD-368.68 MUSD-2024 Q3
5/7/2024-0.77USD-304.28 MUSD-2024 Q1
2/26/2024-0.78USD-281.52 MUSD-2023 Q4
11/6/2023-1.22USD-256.89 MUSD-2023 Q3
8/2/2023-1.28USD-244.17 MUSD-2023 Q2
5/3/2023-1.31USD-236.56 MUSD-2023 Q1
2/22/2023-1.48USD-220.38 MUSD-2022 Q4

EESG©

Eulerpool ESG Scorecard© for the Natera stock

55/100
93
Environment
51
Social
21
Governance
E

Environment

20
Scope 1 - Direct Emissions5,142.88
Scope 2 - Indirect emissions from purchased energy5,713.33
Scope 3 - Indirect emissions within the value chain151,342.95
Total CO₂ emissions10,856.21
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees56
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees59.2
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Natera shareholder structure

% Name
9.62101%
JPMORGAN CHASE & CO
JPMORGAN CHASE & CO
8.75728%
PRICE T ROWE ASSOCIATES INC /MD/
PRICE T ROWE ASSOCIATES INC /MD/
7.67381%
BLACKROCK, INC.
BLACKROCK, INC.
4.31831%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
4.05685%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
3.42719%
WELLINGTON MANAGEMENT GROUP LLP
WELLINGTON MANAGEMENT GROUP LLP
...

Natera Beneficial Ownership Filings (SEC 13D/G)

Free Float
95.6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
10.00%
Matthew Rabinowitz
Matthew Rabinowitz
SEC ↗
9.10%
JPMORGAN CHASE & CO.
JPMORGAN CHASE & CO.
SEC ↗
8.23%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
7.80%
T. Rowe Price Associates, Inc.
T. Rowe Price Associates, Inc.
SEC ↗
7.28%
Alger Group Holdings, LLC
Alger Group Holdings, LLC
SEC ↗
7.20%
13-3017981
13-3017981
SEC ↗
6.70%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
6.43%
Fred Alger Management, LLC
Fred Alger Management, LLC
SEC ↗
6.40%
Dr. Srinivas Akkaraju
Dr. Srinivas Akkaraju
SEC ↗
6.40%
Dr. Anand Mehra
Dr. Anand Mehra
SEC ↗

Natera Executives and Management Board

14 members · avg. age 57 · 29 % women

SC

Mr. Steven Chapman (46)

Chief Executive Officer, Director · since 2010

13.03 M USD

Management

JF

Mr. John Fesko (46)

President, Chief Business Officer

4.89 M USD
SM

Mr. Solomon Moshkevich (43)

President - Clinical Diagnostics

4.89 M USD
MB

Mr. Michael Brophy (45)

Chief Financial Officer

4.89 M USD
DR

Mr. Daniel Rabinowitz (56)

Secretary, Chief Legal Officer · since 2021

3.33 M USD

Board of Directors

MR

Dr. Matthew Rabinowitz (52)

Executive Chairman of the Board, Co-Founder · since 2005

9.83 M USD
JS

Mr. Jonathan Sheena (52)

Co-Founder, Director · since 2007

657,989.00 USD
RB

Mr. Roelof Botha (51)

Lead Independent Director

465,810.00 USD
HR

Mr. Herman Rosenman (77)

Independent Director · since 2014

453,693.00 USD
RC

Dr. Rowan Chapman (54)

Independent Director

453,202.00 USD
GM

Dr. Gail Marcus (68)

Independent Director

448,202.00 USD

Natera Supply Chain

Natera Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
6 companies
#Nameβ 1YTrend
1
Illumina
Supplier·Life Sciences Tools & Services·US
0.95
0.47
0.47
0.68
0.83
0.73
0.96
2
Progyny
Customer·Health Care Providers & Services·US
0.08
0.44
0.43
0.43
0.81
0.68
0.96
3
Personalis
Supplier·Customer·Life Sciences Tools & Services·US
-0.43
0.25
0.68
0.95
0.95
0.62
2.02
4
QIAGEN
Supplier·Customer·Life Sciences Tools & Services·NL
0.15
0.45
0.28
0.87
0.72
0.61
0.55
#Nameβ 1YTrend
1
Roche Holding
Supplier·Customer·Pharmaceuticals·CH
-0.52
-0.03
-0.32
0.10
-0.27
-0.23
-0.20
2
BGI Genomics
Supplier·Customer·Biotechnology·CN
-0.09
-0.21
0.52
0.70
0.70
0.13
—

Frequently asked questions about Natera

Natera Inc operates within the healthcare industry, specifically focusing on genetic testing and diagnostics. As a leading company in molecular diagnostics, Natera specializes in developing and commercializing genetic testing products that aid in reproductive health and oncology. These innovative products include non-invasive prenatal testing (NIPT), preimplantation genetic testing (PGT), and circulating tumor DNA analysis (ctDNA). Natera's business model revolves around providing physicians and patients with advanced genetic testing solutions to help inform medical decisions and improve patient outcomes. With a strong emphasis on research and technological advancements, Natera Inc aims to enhance the standard of care in genetic testing and prenatal screening.

Natera Inc is primarily active in the healthcare industry.

The main competitors of Natera Inc in the market include companies such as Illumina Inc, Invitae Corporation, and Myriad Genetics Inc.

Natera Inc, founded in 2004 and based in California, is a leading genetic testing and diagnostics company. Specializing in reproductive health and genetic disease screening, Natera aims to provide valuable insights for patients and healthcare providers. The company utilizes advanced technologies like cell-free DNA analysis and bioinformatics to develop innovative solutions. Natera's groundbreaking products cover diverse areas such as non-invasive prenatal testing (NIPT), preimplantation genetic testing (PGT), and genetic carrier screening. With a strong commitment to accuracy, reliability, and patient care, Natera Inc continues to pave the way in genetic testing, contributing to improved healthcare outcomes globally.

Natera Inc, a leading genomics company, has achieved significant milestones in its journey. The company has revolutionized non-invasive prenatal testing (NIPT) with its proprietary Panorama® test, providing accurate and early detection of chromosomal abnormalities. Natera Inc has also made remarkable progress in oncology with its Signatera™ personalized oncology assay, empowering clinicians to monitor treatment response and minimal residual disease. Furthermore, the company's ever-expanding menu of genetic tests, including carrier screening and hereditary cancer testing, has positioned it as a trusted partner in personalized healthcare. Natera Inc continues to drive innovation, harnessing the power of genomics to improve patient care and advance precision medicine.

Natera Inc is primarily present in various countries and regions around the world. This includes the United States, where the company is headquartered in San Carlos, California. Natera's presence also extends to other countries such as Canada, the United Kingdom, Germany, France, Spain, Italy, Australia, and many more. With its global reach, Natera Inc offers its innovative genetic testing and diagnostic solutions to individuals and healthcare providers in numerous regions, contributing to advancements in personalized medicine worldwide.

Natera Inc represents values of innovation, accuracy, and compassion in the field of biotechnology. The company is driven by a corporate philosophy focused on transforming the way diseases are detected, managed, and treated. With cutting-edge technology and a commitment to improving patient outcomes, Natera Inc aims to provide advanced genetic testing solutions that revolutionize healthcare. By consistently delivering high-quality diagnostic insights, personalized medicine, and reproductive health solutions, Natera Inc stands as a leader in the industry. Through ongoing research and development, the company strives to empower individuals and healthcare professionals with the knowledge and tools to make informed decisions and improve lives.

Analysts currently set an average price target of 261.00 USD for the Natera stock (median: 267.75 USD), implying -2.5 % versus the latest price. The consensus is based on 27 analyst ratings.

Natera Analyst Price Targets 2026

27 analysts currently rate the Natera stock: 24 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Natera to generate revenue of 2.80 B USD and earnings per share of -1.65 USD.

Natera Analyst Price Targets 2026

Converted at the current exchange rate, the Natera share trades at 232.61 EUR (267.76 USD).

The Natera share (NTRA) is listed on 2 stock exchanges, including: NASDAQ (NTRA), Frankfurt (45E.F).

Natera Inc. is an American biotechnology company based in San Carlos, California. The company focuses on the development and marketing of products and services in the prenatal and reproductive health, cancer diagnostics, and gene therapy fields.

The expected revenue of Natera is 2.80 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Natera is -225.07 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Natera is currently -162.66. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Natera stock.

The price-to-sales ratio (P/S) of Natera is currently 13.09. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Natera stock.

The Eulerpool Quality Score for Natera is 4/10.

The ISIN of Natera is US6323071042. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Natera is A14VPJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Natera is NTRA. The ticker symbol is used to trade Natera shares on the stock exchange.

Natera paid dividends every year for the past 0 years.

Natera is assigned to the 'Health' sector.

The dividends of Natera are distributed in USD.

All fundamentals and in-depth analysis of Natera

Our stock analysis for Natera stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Natera. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Natera Stock
Natera Revenue→
Natera Stock
Natera Net Income→
Natera Stock
Natera P/E→
Natera Stock
Natera P/S→
Natera Stock
Natera EBIT→
Natera Stock
Natera Dividend→
Natera Stock
Natera Directors Dealings→
Natera Stock
Natera Stocks→
Natera Stock
Natera Market capitalization→
Natera Stock
Natera Debt→
Natera Stock
Natera Liabilities→
Natera Stock
Natera Equity→
Natera Stock
Natera AAQS→
Natera Stock
Natera Employees→
Natera Stock
Natera ROE→
Natera Stock
Natera ROA→
Natera Stock
Natera ROCE→
Natera Stock
Natera News→
Natera Stock
Natera Analyst Price Targets→

Health Stocks

National GraphiteNatco PharmaNational HealthcareNarayana HrudayalayaNational Medical Care Company SJSCNanoViricides,National ResearchNanosonicsNatural CapsulesNanoReproNatural Health Farm HoldingsNanologica AB (publ)All Stocks A–Z →